FindTrial
Sign In

The efficacy and safety of systemic anticoagulation in novel coronavirus pneumonia (COVID-19): a medical records based retrospective cohort study

The efficacy and safety of systemic anticoagulation in novel coronavirus pneumonia (COVID-19): a medical records based retrospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039855
Enrollment
Unknown
Registered
2020-11-12
Start date
2020-09-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

anti-coagulate group:Nil
control group:Nil

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients who were diagnosed according to the WHO diagnostic criteria for COVID-19 were included in this study.

Exclusion criteria

Exclusion criteria: 1. Aged < 18 years; 2. Pregnant; 3. had a length of stay <7d; 4. had insufficient medical information.

Design outcomes

Primary

MeasureTime frame
all-cause in-hospital mortality;—

Secondary

MeasureTime frame
d-dimer lever;Weaning from IMV;hemorrhagic complication;thrombocytopenia;—

Countries

China

Contacts

Public ContactBian Yi

Eergency / Intensive Care Department of Tongji Hospital

bianyi2526@163.com+86 15102710366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026